Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease
Andrew McGarry(Cooper Medical School of Rowan University), Michael R. Hayden(Family Research Institute), Karl Kieburtz(University of Rochester), Mark Forrest Gordon(Boehringer Ingelheim (United States)), Michal Geva, Igor D. Grachev(Teva Pharmaceuticals (United States)), Spyridon Papapetropoulos(Teva Pharmaceuticals (United States)), Peggy Auinger(University of Rochester Medical Center), Juha‐Matti Savola(Teva Pharmaceuticals (Switzerland)), Victor Abler(Kansas City VA Medical Center), Sanjay Gandhi(Kansas City VA Medical Center)
Cited by 22
Related Papers
Huntington disease
|Nature Reviews Disease Primers|2015|1.6k
Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
|Nature Genetics|2003|976